Biomarkers for pharmacogenetic and pharmacogenomic studies: Locking down analytical performance.

Drug Discov Today Technol

Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, MD 20850, USA.

Published: July 2014

The use of in vitro tests to detect and measure biomarkers provides promising avenues for development of new and better drugs, and will be central to the realization of personalized medicine. The importance of proper biomarker test assessment cannot be overemphasized. Whether the test is being used as part of drug development or ultimately used as a companion diagnostic, if the test result is to be meaningful, the test analytical performance must be well characterized. This article will outline important analytical validation issues to consider when developing and assessing an in vitro diagnostic test system for use in pharmacogenetic and pharmacogenomic studies.:

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ddtec.2007.10.002DOI Listing

Publication Analysis

Top Keywords

pharmacogenetic pharmacogenomic
8
pharmacogenomic studies
8
analytical performance
8
diagnostic test
8
test
5
biomarkers pharmacogenetic
4
studies locking
4
locking analytical
4
performance vitro
4
vitro tests
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!